Session IX: Colon and Rectal Cancer: Early Disease
The study authors conclude that the combination of preop chemotherapy plus avelumab showed promising activity and a feasible safety profile. According to their statistical considerations, the experimental regimen will be considered for further studies. Updated results are presented during the Congress.
The study authors conclude that based on their analysis, the primary endpoint was successfully met with significant improvement in pathologic complete response (37.5%, p1⁄40.025) and major pathologic response rate rates in the setting of an acceptable safety profile. They note that 3-year disease-free survival and overall survival will be reported later in the final study manuscript.